Stacking up the evidence

Beyond all the ballyhoo, breathless hype, and boisterous claims for ‘a positive trial!’ or even ”practice changing data!’ we saw in Chicago recently, does the clinical evidence really stand up under scrutiny in support?

In some cases yes, but in quite a few cases the answers were a clear no.

So what trials fall into which category, and which yardsticks should we judge them by?

In our latest review we highlight ten clinical studies presented at ASCO and explain some alternative angles to watch out for, with some perspectives from thought leaders included for good measure…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by